Chattem
This article was originally published in The Tan Sheet
Executive Summary
Brands targeted as acquisition candidates likely would be $10 mil.-$50 mil. businesses in the OTC category that are advertising sensitive, Chattem notes during Deutsche Bank Securities Small Cap Growth Conference Feb. 16. The firm states it would stay out of "huge categories with a lot of bigger players." Acquisitions, however, are not a priority for Chattem, as it currently is more interested in licensing new technology for use in skin care and pain relief than buying standalone brands (1"The Tan Sheet" Feb. 6, 2006, p. 6)...
You may also be interested in...
Chattem Looks To Tech: ‘Cool’ New Products Not What They Used To Be
Chattem is focused on acquiring technology rather than new brands, the firm said during a report on fourth-quarter and fiscal year 2005 (ended Nov. 30)
Boehringer Ingelheim, Gubra Enter Third Obesity Deal
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: